The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...

Fintel reports that on November 18, 2025, B of A Securities maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) with a Buy recommendation. As of November 17, 2025, the average one-year price ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...

On Tuesday, H.C. Wainwright reaffirmed its confidence in Werewolf Therapeutics Inc. (NASDAQ: HOWL), maintaining a Buy rating and a ...